Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Yinsheng Zhang

Hongjiang Xu

Xiaojin Wang

Wangwei Ao

Wei Shi

Jie Wu

Jie Wang

Tianxiao Zhao

Yuan Li

Xushi Liu

Xingfeng Ge

Dandan Lu

Li Zhang

Kai Cao

Huan Zhang

Peng Lu

Shuo Chen

Hui Wang

Xueqin Ma

Hangzhou Shen

Jie Ni

Meng Guo

Mingtong Hu

Baomin Liu

Yu Huang

Jing Ren

Beibei Yang

Yin Lu

Pujun Wang

Zhengbang Chen

Zheyang Wu

Kuo Gai

Chao Jin

Xiangyi He

Xiayun Chang

Qinglin Wang

Disclosed are a crystalline form of a five-membered N heterocyclic compound, particularly, a crystalline form of a compound as represented by formula I, and an application of the crystalline form in preparation of a medication for preventing or treating a disease benefiting from inhibition of capsid protein assembly.

Crystal form of five-membered n heterocyclic compound, and application thereof

Disclosed by the present application is a crystalline form of a capsid protein assembly inhibitor containing an N hetero five-membered ring; specifically disclosed is the crystalline form of the compound of formula I; also comprised is an the application of said crystalline form in the preparation of a drug for preventing or treating diseases benefiting from the inhibition of capsid protein assembly.

Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof

Provided is a compound of formula I or II, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and the medical uses thereof in treating diseases benefiting from the capsid protein assembly inhibitor, particularly diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition and uses thereof

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection.

N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof

The present application belongs to the field of pharmaceutical chemistry, and relates to a furo[3,4-b]pyrrole-containing BTK inhibitor, and in particular, to a compound of formula (I), a stereisomer or pharmacologically acceptable salt thereof, a preparation method therefor, a pharmaceutical composition containing the compound, and use thereof in treating BTK-related diseases.

Furo[3,4-b]pyrrole-containing BTK inhibitor

A N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, and a pharmaceutical composition and use thereof, specifically relating to a compound as represented by formula I, a stereoisomer, a tautomer, a geometrical isomer, a solvate, an active metabolite, a hydrate, a prodrug or a pharmaceutically acceptable salt thereof, a pharmaceutical composition thereof, and a medical use thereof. The medical use comprises the use in treating diseases benefiting from the capsid protein assembly inhibitor, and in particular, diseases caused by hepatitis B virus infection. 

The present invention provides a silicon-containing compound for resistance to hepatitis c virus infection, and in particular provides a compound represented by formula I, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, a preparation process therefor, and a pharmaceutical composition comprising the same. The present application also provides a use of the compound, or a pharmaceutically acceptable salt, or a tautomer, or a stereoisomer, or a deuterated compound thereof and mixture among them, and a pharmaceutical composition comprising the same in treatment of hepatitis c virus infection. 

Silicon-containing compound for resistance to hepatitis C virus infection

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

Deuterium-modified brigatinib derivatives, pharmaceutical compositions comprising same, and use thereof

Growing community of inventors

Lianyungang, China

Yinsheng Zhang